Lyra Therapeutics Income Statement (2019-2025) | LYRA

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
0.01M0.27M0.47M0.53M0.36M0.01M0.41M0.46M0.54M0.15M0.53M0.60M0.20M0.21M0.18M0.18M0.03M0.01M
Operating items
Research & Development (Quarter)
4.77M7.50M7.08M10.34M8.51M10.79M10.05M9.45M12.60M10.80M12.37M12.27M18.24M13.26M5.90M6.36M4.88M5.11M4.05M4.38M
Selling, General & Administrative (Quarter)
3.06M3.56M4.02M3.57M3.89M4.13M5.14M4.40M5.13M4.57M5.00M4.36M5.82M5.14M3.93M3.61M3.26M3.50M2.24M2.54M
Restructuring Costs (Quarter)
6.45M2.80M1.65M0.90M0.40M-0.02M0.24M
Other Operating Expenses (Quarter)
1.32M1.59M24.72M-0.00M-0.01M-0.03M
Operating Expenses (Quarter)
7.83M11.06M11.10M13.91M12.39M14.93M15.19M15.17M17.72M16.96M17.37M16.62M24.06M49.57M12.64M11.62M9.02M9.01M6.26M7.12M
Operating Income (Quarter)
-7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M-7.12M
EBIT (Quarter)
-7.83M-11.06M-11.08M-13.64M-11.93M-14.40M-14.83M-15.15M-17.31M-16.50M-16.83M-16.48M-23.52M-48.97M-12.44M-11.41M-8.84M-8.83M-6.24M-7.12M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.03M0.03M0.02M0.01M0.03M0.06M0.93M1.07M0.90M1.19M1.34M1.09M0.85M0.58M0.43M0.30M0.41M0.26M0.17M
Non Operating Income (Quarter)
0.03M0.03M0.03M0.02M0.01M0.03M0.06M0.93M1.07M0.90M1.19M1.34M1.09M0.85M0.58M0.43M0.30M1.39M0.26M0.17M
Net income details
EBT (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.24M-15.61M-15.63M-15.14M-22.44M-48.12M-11.87M-10.97M-8.54M-7.43M-5.98M-6.95M
Tax Provisions (Quarter)
0.01M0.01M0.02M0.02M0.01M0.01M0.01M0.01M0.00M0.00M0.00M0.00M
Profit After Tax (Quarter)
-7.80M-11.04M-11.05M-13.60M-11.91M-14.37M-14.77M-14.26M-16.25M-15.62M-15.65M-15.18M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M-6.93M
Income from Continuing Operations (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M-6.95M
Consolidated Net Income (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M-6.95M
Income towards Parent Company (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M-6.95M
Net Income towards Common Stockholders (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.25M-15.62M-15.65M-15.16M-22.45M-48.13M-11.87M-10.98M-8.55M-7.44M-5.98M-6.95M
Additional items
EPS (Basic) (Quarter)
-0.60-0.85-0.85-1.05-0.92-0.42-0.40-0.36-0.44-0.36-0.27-0.22-0.35-36.76-9.07-8.30-0.13-5.51-3.38-3.77
EPS (Weighted Average and Diluted) (Quarter)
-0.60-0.85-0.85-1.05-0.92-0.42-0.40-0.36-0.44-0.36-0.27-0.22-0.35-36.76-9.07-8.30-0.13-5.51-3.38-3.77
Shares Outstanding (Weighted Average) (Quarter)
12.95M12.97M13.00M12.99M13.01M23.54M36.83M5.00M36.83M43.68M56.95M0.20M64.01M1.29M8.61M1.30M8.61M1.02M1.02M1.55M
Shares Outstanding (Diluted Average) (Quarter)
12.95M12.97M12.98M12.99M13.01M23.54M28.01M30.24M36.83M43.68M45.89M49.80M64.01M1.29M1.30M1.30M65.76M1.35M1.77M1.55M
EBITDA (Quarter)
-7.80M-11.04M-11.05M-13.62M-11.91M-14.37M-14.77M-14.22M-16.28M-15.63M-15.63M-15.12M-22.46M-48.16M-11.85M-11.00M-8.55M-7.44M-5.98M-6.95M
Shares Outstanding (Quarter)
12.96M13.00M13.00M13.01M13.01M31.83M31.83M31.83M31.84M49.55M49.55M1.14M1.22M1.31M1.31M1.31M1.32M1.63M1.64M1.77M
Tax Rate (Quarter)
-0.09-0.08-0.10-0.11-0.06-0.02-0.06-0.05-0.05-0.03-0.05-0.03